Rifampicin reduces plasma concentrations of moxifloxacin in patients with tuberculosis. - Wikidata - wikimedia - TriplyDB

Rifampicin reduces plasma concentrations of moxifloxacin in patients with tuberculosis.

Rifampicin reduces plasma concentrations of moxifloxacin in patients with tuberculosis.

http://www.wikidata.org/entity/Q30834393

about

Pharmacokinetic drug interactions of antimicrobial drugs: a systematic review on oxazolidinones, rifamycines, macrolides, fluoroquinolones, and Beta-lactams Emerging strategies for the treatment of pulmonary tuberculosis: promise and limitations?Pharmacokinetic Aspects of the Two Novel Oral Drugs Used for Metastatic Castration-Resistant Prostate Cancer: Abiraterone Acetate and Enzalutamide Current treatment of atypical mycobacteriosis Gender analysis of moxifloxacin clinical trials Insights into the pharmacokinetic properties of antitubercular drugs.Pharmacokinetics of antituberculosis drugs in pulmonary tuberculosis patients with type 2 diabetes Comparative study on genotypic and phenotypic second-line drug resistance testing of Mycobacterium tuberculosis complex isolates.Testing tuberculosis drug efficacy in a zebrafish high-throughput translational medicine screen Pharmacokinetics and safety of moxifloxacin in children with multidrug-resistant tuberculosis.Mycobacterial brain tuberculomas due to Bacille Calmette-Guérin intravesical chemotherapy for bladder cancer: A case report and literature review.Pharmacokinetic Modeling and Optimal Sampling Strategies for Therapeutic Drug Monitoring of Rifampin in Patients with Tuberculosis.Correlation between GyrA substitutions and ofloxacin, levofloxacin, and moxifloxacin cross-resistance in Mycobacterium tuberculosis.Effect of rifampicin & isoniazid on the steady state pharmacokinetics of moxifloxacin Accumulating Evidence and Research Organization (AERO) model: a new tool for representing, analyzing, and planning a translational research program.Repeated administration of high-dose intermittent rifapentine reduces rifapentine and moxifloxacin plasma concentrations.Treatment of tuberculosis in children.New drugs against tuberculosis: problems, progress, and evaluation of agents in clinical development.High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial.Rifampin combination therapy for nonmycobacterial infections.Current pharmacotherapy options for osteomyelitis: convergences, divergences and lessons to be drawn.Clinical pharmacokinetics of antibacterials in cerebrospinal fluid.Pharmaceutical applications of the Calu-3 lung epithelia cell line.Therapeutic drug monitoring in the treatment of tuberculosis: an update.Current concepts in the management of prosthetic joint infection.Influence of daily dosage and frequency of administration of rifampicin-levofloxacin therapy on tolerance and effectiveness in 154 patients treated for prosthetic joint infections.Antituberculosis drugs in children.New Paradigm for Translational Modeling to Predict Long-term Tuberculosis Treatment Response.Effect of rifampicin and efavirenz on moxifloxacin concentrations when co-administered in patients with drug-susceptible TB.A Review of Moxifloxacin for the Treatment of Drug-Susceptible Tuberculosis.Are moxifloxacin and levofloxacin equally effective to treat XDR tuberculosis?Antagonistic effect of rifampin on the efficacy of high-dose levofloxacin in staphylococcal experimental foreign-body infection Moxifloxacin population pharmacokinetics in patients with pulmonary tuberculosis and the effect of intermittent high-dose rifapentine.Oral antibiotic therapy.Efficient measurement and factorization of high-order drug interactions in Mycobacterium tuberculosis Advances in the treatment of pulmonary tuberculosis.Moxifloxacin Is a Potent In Vitro Inhibitor of OCT- and MATE-Mediated Transport of Metformin and Ethambutol.The pharmacokinetics and pharmacodynamics of pulmonary Mycobacterium avium complex disease treatment.P-glycoprotein-mediated transport of moxifloxacin in a Calu-3 lung epithelial cell model.Plasma and cerebrospinal fluid pharmacokinetics of moxifloxacin in a patient with tuberculous meningitis.

P2860

Q24631021-D6D5AA87-5231-418C-8B67-2DC257316F97 Q26771997-2F9A9D59-02B4-4CC0-8D7C-EF5CA077C22F Q28076820-516571EF-8DE8-4482-A050-24CC25C91EA2 Q28265322-4D0AFDEB-D133-43F2-BB4E-4B1EA2703507 Q28538319-ABBB6938-90A6-4051-AAA1-0CFB09D4A669 Q30251497-42C5D77D-2193-425E-9C5D-96E81C6F189D Q33521011-5578A924-E1E6-48CC-8AFC-E10F59F39699 Q34046259-DF0E49BA-2E27-4F44-8288-993C2E1180C7 Q35106008-F5EA88D4-5805-49D9-BB41-4154EC5102E9 Q35197257-E92CB591-8174-4BCD-9C2E-DDD0E833DBDB Q35434020-C1BE62B0-C606-45B8-A5D5-88EEB09E752A Q35859862-562C5380-EE90-4410-9608-ADF61088DC06 Q35960685-FE5A8C84-C633-4486-B8A4-9CD5D6BE7850 Q36728692-8D882483-B926-45CC-A7E4-717F63973CB8 Q36905756-E66F88A1-4247-45F5-9B11-D2AF5C38D14B Q36949454-F7005175-9630-4236-80BC-7476BD839537 Q37340569-5CAC05E9-197E-466A-BA96-C29EF784C3A7 Q37346929-E3CD5B75-AAF9-4D54-BFE5-96CA9FF3F2C8 Q37507802-2E9D7493-550A-4C7B-BF7E-9FEDF716A224 Q37672039-1D9FFC7D-A3A4-4740-B6E6-ACE6800CF51E Q38089918-41CDA8FB-A35C-4EB3-B958-892A3F1582A3 Q38100704-72C9C0BA-3AE0-464C-AFBE-37CA2E76E4B7 Q38111427-72E0CE81-9FCE-43AA-A4EE-6F02089AA9A9 Q38213320-3D217D60-DE32-4938-B918-C0A0FDEFFDF7 Q38221335-42AF80AA-6A6E-4519-8315-90A122A4A51A Q38490164-0EAC455D-0A70-4517-A733-9CA2A65500FD Q38533435-C9AE67C1-94C8-4E32-BDAC-119C38D35422 Q38754367-943D8257-99E1-4CB2-9E62-063CE565F15A Q38973113-DE9853D3-A0DD-4DDA-BF18-742130789701 Q39456569-029DBB9C-159D-4285-9318-4232DFD81EA2 Q40202149-B2FDEDCE-AF6C-428C-B8EF-9583707A5E19 Q41913615-E34BB041-CD7D-421B-9531-F1F0E98B02FC Q41962727-CB89F4B8-133B-4C72-A89D-D741968D1B95 Q42231206-B5466EB3-6B6A-456C-934A-045AACB82E67 Q42263053-620229E9-6C1F-4ADC-8F31-C8EE7AD1239D Q42355284-4B844F45-763F-4BB2-B348-057A2574716E Q42364862-7437AC3A-958D-462D-8628-3A1508343623 Q42717214-21BBD42E-FACD-43F3-9CBD-B9B1A486CEB6 Q43075165-0DCBA888-702F-4C77-8103-68F96D5C771E Q43253700-6B7E53A7-F3C7-4D54-A10E-A190D4F62B2D

P2860

Rifampicin reduces plasma concentrations of moxifloxacin in patients with tuberculosis.

http://www.wikidata.org/entity/Q30834393

description

2007 nî lūn-bûn

@nan

2007 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2007 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

name

Rifampicin reduces plasma concentrations of moxifloxacin in patients with tuberculosis.

@ast

Rifampicin reduces plasma concentrations of moxifloxacin in patients with tuberculosis.

@en

type

label

Rifampicin reduces plasma concentrations of moxifloxacin in patients with tuberculosis.

@ast

Rifampicin reduces plasma concentrations of moxifloxacin in patients with tuberculosis.

@en

prefLabel

Rifampicin reduces plasma concentrations of moxifloxacin in patients with tuberculosis.

@ast

Rifampicin reduces plasma concentrations of moxifloxacin in patients with tuberculosis.

@en

P1433

Q30834393-68463CB4-D38A-4A8C-8DFB-D0AE296AF4A5

P1476

Q30834393-86EB7C08-9552-485F-BF22-A83EA2D3F364

P2093

Q30834393-17B1C60E-FDF4-464F-9696-B76AE18C9426

Q30834393-17E1ED96-79BB-40E9-9A1F-CE8E3F40C658

Q30834393-493B84FE-1ED8-4DAD-887E-C668E1607EAB

Q30834393-5967BCC3-38EA-4445-9FD9-779C60A44C56

Q30834393-A47B3120-31EA-42B6-B6A9-D569B96012E4

Q30834393-E612C319-BCB1-40DB-8D31-2A8930A82B67

Q30834393-F0F59493-40AC-4B21-B356-89BC8E41FCA2

P2860

Q30834393-0C55899D-0EB5-462E-8722-19E8998D171C

Q30834393-0D473D43-C1A3-472F-9219-DD77E80FFC2C

Q30834393-1EDD6437-FC2C-454B-938E-A7987A988D4F

Q30834393-20E345CF-AAAB-45C1-BFCB-40987AF9B4F6

Q30834393-28E0F9F4-77A5-4D7F-B26A-E4CC237732BF

Q30834393-3F8B2045-974B-4BB8-8B88-923385E49C9A

Q30834393-4B10F9AA-7CEE-4452-9B6D-B4776450475B

Q30834393-597F2068-0E38-43AC-80BC-8BA62502A26B

Q30834393-5C0E67DA-42FB-4779-A2B9-0C1AC3C49B1D

Q30834393-5C6F98BA-E3BF-416D-A7D0-F26EE4ECFE67

P304

Q30834393-E07A297A-F779-430E-9F9A-349DB4F7C879

P31

Q30834393-217A2218-3CC7-4570-84F1-D63F627366AE

P356

Q30834393-33666407-80B0-41B7-B16B-92EB8C62CDBE

P407

Q30834393-0EDBEAA2-A2AE-49FE-8ACC-EAB458CDCAC6

P433

Q30834393-7B5B4421-5035-4278-85D8-B5DF25CD066D

P478

Q30834393-8ABA9B87-9858-4A28-9144-04826F9CA469

P577

Q30834393-9F2F0653-B394-49AD-9A2E-2B378356D508

P5875

Q30834393-5D8A621F-2D3C-4558-8720-DCFBB4B0202A

P698

Q30834393-2B331BDF-2455-44B1-9C98-80B7B2896104

P921

Q30834393-D4648170-66FE-47D3-AD56-F11898D067A5

P356

P1433

Clinical Infectious Diseases

P1476

Rifampicin reduces plasma concentrations of moxifloxacin in patients with tuberculosis.

@en

P2093

A Juwono Suroto

http://www.w3.org/2001/XMLSchema#string

B Alisjahbana

http://www.w3.org/2001/XMLSchema#string

D M Burger

http://www.w3.org/2001/XMLSchema#string

H M J Nijland

http://www.w3.org/2001/XMLSchema#string

R E Aarnoutse

http://www.w3.org/2001/XMLSchema#string

R Ruslami

http://www.w3.org/2001/XMLSchema#string

R van Crevel

http://www.w3.org/2001/XMLSchema#string

P2860

Mutant prevention concentration as a measure of antibiotic potency: studies with clinical isolates of Mycobacterium tuberculosis

American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America

Pharmacokinetics and tolerability of a higher rifampin dose versus the standard dose in pulmonary tuberculosis patients.

Isoniazid drug and food interactions.

Pharmacokinetics of rofecoxib: a specific cyclo-oxygenase-2 inhibitor.

Clinical pharmacology of the fluoroquinolones: studies in human dynamic/kinetic models.

Application of fluoroquinolone pharmacodynamics.

The physiological kinetics of nitrogen and the prevention of decompression sickness.

Moxifloxacin-containing regimen greatly reduces time to culture conversion in murine tuberculosis.

Moxifloxacin-containing regimens of reduced duration produce a stable cure in murine tuberculosis.

P304

1001-1007

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1086/521894

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

45

http://www.w3.org/2001/XMLSchema#string

P577

2007-09-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5963022

http://www.w3.org/2001/XMLSchema#string

P698

17879915

http://www.w3.org/2001/XMLSchema#string

P921

Akafuba bulwadde